Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

Abstract: Compositions comprising a reaction product of a saccharide polymer and a fatty ester may be obtained in an aqueous phase in the presence of a hydroxide base and a neutral surfactant, the saccharide polymer comprising a dextran, a dextrin compound, or any combination thereof. The compositions also comprise one or more alcohols originating from the fatty ester upon forming the reaction product of the saccharide polymer and the fatty ester. The reaction product of the saccharide polymer and the fatty ester may be present in the aqueous phase at a concentration effective to lower a surface tension of the neutral surfactant. The fatty ester may comprise one or more glycerol esters, such as one or more plant and/or animal oils and/or fats, and the one or more alcohols originating from the fatty ester may comprise glycerol. Fatty acids originating from the fatty ester may be substantially straight-chain fatty acids.

Abstract: Described is an aqueous composition comprising: (a) at least one non-ionic cellulose ether, and (b) benzoic acid within the range of from 0.2 wt % to 0.3 wt % based on the total weight of the composition, wherein said composition has a viscosity equal to or above 24 000 cP, an osmolality of from 100 to 400 mOsmol/kg, and a pH of from 3 to 5. The aqueous composition may be used in the treatment and/or prevention of a human fungal infection such as a vaginal fungal infection.

Abstract: A stable pharmaceutical or dermo-cosmetic aqueous solution of epigallocatechin gallate is provided. The present solution has improved EGCG solubility, stability and bioavailability.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.

Abstract: The subject invention provides materials and methods for preventing, inhibiting or reducing biofilm formation and biofilm infections, in particular, in the respiratory tract of a subject. The invention utilizes growth by-products of beneficial microorganisms to enhance the effectiveness of biocidal substances in the treatment, disruption and/or prevention of biofilms. Advantageously, the subject invention is useful against antibiotic-resistant bacterial strains, such as MRSA, Helicobacter pylori, S. pneumoniae, P. aeruginosa and A. fumigatus.

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Abstract: Personal care compositions and methods for preparing the same are disclosed. The personal care composition may include an emulsifying system, one or more emollients, and one or more humectants. The method for preparing the personal care composition may include contacting the emulsifying system, the one or more emollients, and the one or more humectants with one another.

Abstract: Provided are skincare compositions that include a bactericide, one or more surfactants, water, and optionally saturated fatty acid. The composition may include a bactericide, surfactants (e.g., anionic and/or zwitterionic), saturated fatty acid, and no more than about 50 wt % water. Alternatively, the composition may include a bactericide, surfactants (e.g., anionic and/or nonionic), and at least about 50 wt % water. Commonly, the skincare compositions may include benzoyl peroxide and goat milk. The compositions may be used for various applications including cleaning the skin and as a shaving cream.

Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.

Abstract: In one aspect, the invention relates to binary compositions that disrupt ORco-mediated odorant sensing. In particular, compounds and compositions are provided that can inhibit sensory (e.g., host targeting) functions in organisms that express ORco receptors such as airborne insects, e.g., mosquitos, and ticks. Methods of employing such agents, and articles incorporating the same, are also provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The present invention provides an oral care composition which includes one or more nonpolar structuring agents, one or more emulsifiers, one or more mucoadhesive polymers, and one or more active ingredients effective for providing oral pain relief. The oral care composition can be a solid or semi-solid composition up to a temperature of at least 40° C. Methods of providing such an oral care composition are also provided herein.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.